Acumen Pharmaceuticals (NASDAQ:ABOS) Downgraded by Zacks Investment Research to “Sell”

Acumen Prescribed drugs (NASDAQ:ABOSGet Ranking) was downgraded by Zacks Financial investment Investigate from a “hold” rating to a “sell” ranking in a investigate be aware issued to investors on Tuesday, stories.

According to Zacks, “Acumen Pharmaceuticals Inc. is a scientific-phase biopharmaceutical company. It concerned in producing a novel ailment for Alzheimer. The company’s product pipeline consist ACU193. Acumen Prescription drugs Inc. is based mostly in CHARLOTTESVILLE, Va. “

Several other brokerages also not long ago issued stories on ABOS. Credit Suisse Group reduced their price goal on Acumen Prescription drugs from $26.00 to $17.00 and established an “outperform” rating on the inventory in a research report on Tuesday, March 29th. Lender of America elevated Acumen Pharmaceuticals from a “neutral” rating to a “buy” score and lowered their rate focus on for the company from $16.00 to $14.00 in a investigate report on Friday, January 21st. One particular analyst has rated the inventory with a sell score and 4 have issued a buy rating to the inventory. According to information from, Acumen Prescribed drugs at the moment has a consensus score of “Buy” and a consensus value focus on of $18.35.

Acumen Pharmaceuticals inventory traded up $.27 through mid-day buying and selling on Tuesday, hitting $3.58. 12,353 shares of the company’s stock were being exchanged, compared to its ordinary quantity of 243,723. Acumen Pharmaceuticals has a 1-yr very low of $3.25 and a 1-12 months higher of $26.98. The inventory has a 50 working day relocating average of $4.63 and a two-hundred day moving ordinary of $6.71.

A quantity of institutional investors and hedge funds have recently produced modifications to their positions in the business enterprise. Deutsche Lender AG obtained a new stake in shares of Acumen Prescription drugs throughout the 3rd quarter really worth somewhere around $82,000. Pura Vida Investments LLC acquired a new stake in shares of Acumen Prescription drugs in the 3rd quarter valued at close to $1,115,000. Goldman Sachs Group Inc. acquired a new stake in shares of Acumen Pharmaceuticals in the third quarter valued at around $946,000. BlackRock Inc. obtained a new stake in Acumen Pharmaceuticals through the 3rd quarter really worth $42,629,000. Eventually, BVF Inc. IL acquired a new position in shares of Acumen Prescribed drugs in the course of the 3rd quarter really worth $4,304,000. Hedge cash and other institutional buyers personal 64.42% of the company’s stock.

About Acumen Prescribed drugs (Get Score)

Acumen Prescription drugs, Inc, a clinical-phase biopharmaceutical firm, discovers and develops therapies for the procedure of Alzheimer’s ailment. The organization focuses on advancing a focused immunotherapy drug prospect ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to goal soluble amyloid-beta oligomers.

See Also

Get a absolutely free duplicate of the Zacks analysis report on Acumen Prescription drugs (ABOS)

For far more details about study choices from Zacks Investment Study, visit

Want More Great Investing Strategies?

Get Information & Scores for Acumen Pharmaceuticals Each day – Enter your e-mail address below to receive a concise every day summary of the latest news and analysts’ scores for Acumen Prescription drugs and connected businesses with’s Free daily e-mail newsletter.